» Articles » PMID: 30217540

Post-operative Electrode Location and Clinical Efficacy of Subthalamic Nucleus Deep Brain Stimulation in Meige Syndrome

Overview
Specialty Neurology
Date 2018 Sep 16
PMID 30217540
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Subthalamic nucleus (STN) deep brain stimulation (DBS) has recently been shown to be an effective treatment for Meige syndrome but efficacy of symptomatic improvement and its relationship to factors in DBS remains to be explored.

Objectives: This study explored the relationship of electrode contact location in bilateral STN-DBS with clinical efficacy in Meige syndrome patients through retrospective analysis.

Methods: Pre- and post-operative magnetic resonance (MR) images of Meige syndrome patients (n = 15) were analysed. Clinical outcomes were evaluated with the Burke-Fahn-Marsden Dystonia Scale (BFMDRS). The location of active contacts in Montreal Neurological Institute (MNI) standard space and volume of activated STN tissue were determined and related to clinical outcomes.

Results: At the last follow up (mean = 14.8 ± 4.0 months; range = 11-24 months), Meige syndrome patients (n = 14) showed improved BFMDRS scores (mean improvement = 70.9%, p = 0.001) compared to pre-operative assessment. Active contacts of stimulation given from coordinates in the MNI space (mean left side: x = -12.5 ± 1.2 mm, y = -13.3 ± 1.7 mm, z = -5.5 ± 2.5 mm; mean right side: x = 12.7 ± 1.4 mm, y = -12.7 ± 1.7 mm, z = -6.4 ± 2.4 mm) were found mainly clustered in the dorsolateral STN. While there were no significant differences in patients grouped by their degree of symptomatic improvement (<30%, 30-70% and >70%) with their respective coordinates, the volume of activated tissue within the STN of patients was significantly correlated to the BFMDRS improvement (R = 0.6, p = 0.02).

Conclusions: These findings further support the stimulation of the dorsolateral STN for effective alleviation of symptoms in Meige syndrome patients and indicate that specific factors of DBS can be considered to predict clinical efficacy.

Citing Articles

Putaminal-cortical circuits predict response of bilateral deep brain stimulation of the subthalamic nucleus in the primary Meige syndrome after 5 years.

Wang N, Wu Y, Yao C, Meng D, Zhang H, Cheng Q Brain Commun. 2025; 7(1):fcaf042.

PMID: 39944744 PMC: 11814497. DOI: 10.1093/braincomms/fcaf042.


Effects of onabotulinum toxin type A injections in patients with Meige's syndrome.

Duarte A, Coutinho L, Germiniani F, Teive H Arq Neuropsiquiatr. 2024; 82(4):1-7.

PMID: 38641339 PMC: 11031253. DOI: 10.1055/s-0044-1785691.


Pallidal versus subthalamic deep brain stimulation for Meige syndrome: A systematic review and meta-analysis.

Wu X, Xue T, Pan S, Xing W, Huang C, Zhang J Heliyon. 2024; 10(6):e27945.

PMID: 38510025 PMC: 10950702. DOI: 10.1016/j.heliyon.2024.e27945.


Subthalamic deep brain stimulation for primary dystonia: defining an optimal location using the medial subthalamic nucleus border as anatomical reference.

Zhao M, Chen H, Yan X, Li J, Lu C, Cui B Front Aging Neurosci. 2023; 15:1187167.

PMID: 37547744 PMC: 10400903. DOI: 10.3389/fnagi.2023.1187167.


Bilateral pallidal DBS for blepharospasm: A case report and review of the literature.

Lucas J, Kusyk D, Whiting D Surg Neurol Int. 2022; 13:200.

PMID: 35673639 PMC: 9168297. DOI: 10.25259/SNI_1234_2021.